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A B S T R A C T
This study aimed to determine the etiology, treatment protocol and outcome of convulsive status
epilepticus (SE) in children. An institutional treatment protocol using benzodiazepines (diazepam and
midazolam) was assessed in a retrospective case study. The treatment protocol (Ege Pediatric Status
Epilepticus Protocol or EPSEP) was developed based on an operational deﬁnition of pediatric SE
according to the duration of seizure activity. Pediatric SE is divided into three categories: initial SE (20–
30 min), established SE (30–60 min) and refractory SE (>60 min). Eight (30%) of the studied episodes
were initial SE, 10 (37%) were established SE, and 9 (33%) were refractory SE. With respect to the
etiological spectrumof SE, 11 (40%) children hadmeningitis or encephalitis. Febrile SEwas identiﬁed in 7
(26%) patients. Only 2 episodes of initial SE (7.5%) were controlled with ﬁrst step of the protocol (two
concomitant-doses of rectal diazepam). Midazolam bolus and infusions (up to 1.2 mg/kg/min) were used
to treat 22 episodes of SE (9 refractory SE, 10 established SE and 3 initial SE). Complete arrest of
convulsive SE was achieved in 21 of 22 (95%) episodes with midazolam infusion. We concluded that the
combined use of benzodiazepines (diazepam + midazolam) was safe and effective in the treatment of
convulsive SE in children.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is a serious neurological problem in
children. Both convulsive and nonconvulsive SE affects people of
all ages, though it is more common and causes greater morbidity
and mortality in infants.1–5 Age, etiology, and the duration of
seizure activity correlate with mortality.6
Convulsive SE deﬁned as a seizure lasting more than 30 min or
recurrent seizures lasting more than 30 min from which the
patient does not regain consciousness (ILAE, 1981). However the
current deﬁnition of 30 min is not universally accepted, and
several clinical studies have been published using duration of 10 or
20 min.6,7 It has been reported that the mortality is nearly 10-fold
higher for seizure lasting 30 min or longer than for those lasting
10–29 min.7
The optimal management of children with SE remains unclear,
and large, controlled studies comparing the various agents are* Corresponding author at: Ege University School of Medicine, Department of
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doi:10.1016/j.seizure.2010.10.034lacking. All patients with SE must be managed with aggressive
monitoring of their hemodynamic and respiratory status and
continuous EEG monitoring. There are multiple regimens for
treating SE in children.8–10 The choice of initial agent may depend
on individual patient characteristics, prior antiepileptic drug
therapy, and physician preference. However more information is
needed to develop a structured treatment regimen based on an
operational deﬁnition for SE.
In this study we aimed to determine the etiology and outcome
of SE in children treated according to an institutionalized
treatment regimen (Ege Pediatric Status Epilepticus Protocol or
EPSEP).
2. Subjects/methods
This study included 27 children suffering from convulsive SE
admitted to the intensive care unit of Ege University Hospital. The
children were managed according to a structured protocol for
pediatric status epilepticus. SE is diagnosed according to the
established criteria of continues seizures for 30 min or longer or
several seizures occurring with impairment of consciousness
between seizures.6,7,11,12 Initial SE consists of the ﬁrst 10–20 min
of the epileptic state, during which physiological mechanismsvier Ltd. All rights reserved.
Table 1
Patients demographics and classiﬁcation of status epilepticus.
Initial SE (20–30min) Established SE (>30min) Refractory SE (>60min) Total
Number of patients (%) 8 (30%) 10 (37%) 9 (33%) 27
Boys/girls 3/5 7/3 7/2 17/10
Age years (range) 2.6 (1–5) 3.4 (0.6–10) 5.5 (02–11) 3.8 (0.2–11)
Febrile/afebrile 5/3 6/4 2/7 13/14
Lethargy (%) 8 (30%) 10 (37%) 5 (18%) 23 (85%)
Coma – – 4 (15%) 4 (15%)
Table 2
Ege Pediatric Status Epilepticus Protocol (EPSEP) in children with convulsive status
epilepticus.
Pediatric convulsive status epilepticus (SE)
n=27
Step I









Established SE (>30min) n=10 (37%) Midazolam (infusion up to 0.6mg)
responsive (n=10, 52%)
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lished SE is deﬁned as the stage beyond 30 min, where the status
continues despite early-stage treatment. It is during this phase that
physiological compensation mechanisms begin to fail. If seizures
continue for 60–90 min after the initiation of therapy, SE is
considered refractory. In this study SE patients were divided it into
three group based on the duration of continuing convulsive seizure
activity: initial SE (20–30 min seizure activity), established SE
(>30 min) and refractory SE (>60 min).
EEG was not used for the diagnosis of convulsive SE. Instead it
was performed after the seizures had been controlled to monitor
the electrical suppression of seizure discharges. However, EEG was
used initially to conﬁrm any diagnosis of nonconvulsive SE. The
diagnosis of nonconvulsive SE was based on established criteria.13
All children underwent imaging of the brain (computed tomogra-
phy or magnetic resonance imaging) and relevant investigations,
including metabolic work-up, when indicated. Other demographic
characteristics such as age, sex, mental status and underlying
disease, were recorded for each patient.
A structured institutional treatment regimen of pediatric status
epilepticus (Ege Pediatric Status Epilepticus Protocol or EPSEP) has
been used since 2004 in the emergency room (ER) and the pediatric
intensive care unit (PICU) of Ege University Hospital. The protocol
was developed based on the characteristics of the ER and the PICU.
Since the release of rectal diazepam in Turkey we have not used
intravenous diazepam in the initial management of SE. Phenytoin
and midazolam were introduced as second-line medication in the
protocol because of the lack of certainmedications (e.g., lorazepam
and fosphenytoin) in Turkey.
 Step I: Children who presented with prolonged seizure (>5 min)
received two repeated doses of 0.5 mg/kg of rectal diazepam
during the ﬁrst 10 min of the episode.
 Step II: After 15 min of episodes, one of the following second line
drugwas administered (1) 20 mg/kg of intravenous phenytoin or
(2) a bolus of midazolam (0.15 mg/kg iv).
 Step III: If the child continued to exhibit SE, the amount of
intravenous midazolam was increased every 5 min up to 0.6 mg/
kg/min. After achieving seizure control, the infusion was
continued for at least 24 h. Subsequently, midazolam infusion
was gradually decreased by 0.05mg/kg/min every 6 h until
tapering was completed. If a seizure continued for 60 min after
the infusion (0.6mg/kg/min), the amount of midazolam the
maintenance infusionwas increased up to 1.2mg/kg/min. During
this infusion, vital parameters such as the respiratory rate, heart
rate, blood pressure, and arterial oxygen saturation were
monitored continuously.
 Step IV: If seizures continued for 60–90 min after the initiation of
therapy propofol infusion (1 mg/kg/h) was introduced.
3. Results
There were 17(63%) boys and 10(37%) girls admitted with
status epilepticus (SE). The age of the patients ranged from 2.5
months to 11 years, with a mean of 3.8  1.8 years. Eight episodes(30%) were initial SE, 10 (37%) were established SE, and 9 (33%) were
refractory SE.
Twenty-three patients (85%) were assessed as lethargic (10,
established SE; 8, initial SE; 5, refractory SE) and 4 (15%) children
were in coma when they arrived at the PICU (Table 1). At the time
of admission to the PICU, children in comas were more likely to
have refractory SE (p < 0.001) (95% CI).
With respect to the etiological spectrum of SE, 11 (40%) children
had meningitis or encephalitis. Febrile SE was identiﬁed in 7 (26%)
patient. Five (19%) had cerebral cortical dysgenesis, 3 (11%) had
hypoxic ischemic encephalopathy, and 1 had trauma. While the
majority (85%: 11 out of 13) febrile episodes occurred in younger
patients, afebrile refractory episodes more likely to be seen in older
patients (53.3%: 8 out of 15) (p = 0.004) (95% CI). Of the 9 children
with refractory SE, 7 had meningitis or encephalitis and 2 had
cerebral cortical dysgenesis,. Noneof the childrenwith febrileSEhad
refractory SE.
Only 2 of 27 (7.5%) episodes of SE were controlled by step I of
EPSEP (two concomitant does of rectal diazepam). Three of the
patients with initial SE had cardiovascular contraindications
during the phenytoin infusion in step II of EPSEP that might be
related to the phenytoin infusion (2 had hypotension and 1 had
drug extravasation).
Midazolam infusion was used to treat 22 episodes of SE (9
refractory SE, 10 established SE and 3 initial SE). Complete arrest of
seizures was achieved in 21 of the 22 (95%) patients (p < 0.001)
(95% CI). Continuous midazolam infusion up to 1.2mg/kg/min was
effective in 8 of 9 (89%) of the children with refractory SE without
signiﬁcant side effects. One episode of refractory SE was controlled
by intravenous propofol infusion (Table 2).
After midazolam infusion, adverse events were seen in 4
patients (20%). Therewas a transient drop in oxygen saturation in 1
child. This child had received per-rectal diazepam (2  0.5 mg/kg)
and phenytoin prior to midazolam infusion. To improve the child’s
oxygen saturation, oxygen was administrated by facemask for less
E.U. Saz et al. / Seizure 20 (2011) 115–118 117than 24 h. There were 3 children with mild hypotension who
required only intravenous ﬂuids, after which they remained
normotensive.Three childrenneeded intubationas theyexperienced
respiratory arrest following per-rectal diazepam plus phenytoin (2
two children) and midazolam infusion followed propofol (1 child).
No serious intervention was needed. During the management of SE,
the electrolytes and glucose remained normal in all patients.
There were no deaths within one year of the episode of SE in the
27 children included in the cohort. However, at the one-year
follow-up 4 children (14.8%) developed new either motor or visual
deﬁcit in the refractory SE group (40%) and none of the patient from
the initial and established SE groups had neurological deﬁcits
(p < 0.001, CI 95%). All of the children with neurological sequelae
had refractory SE due to encephalitis. None of the children with
febrile SE had neurological sequelae.
4. Discussion
Convulsive SE is themost common formof status epilepticus and
is estimated to account for about 90% of all cases in children.14–17
Herewe report that EgePediatric Status EpilepticusProtocol (EPSEP)
outlined in the Subjects andMethods section is an effective and safe
regimen for the treatment of children with convulsive SE.
Most cases of SE can be treated successfully with ﬁrst-line
medications (e.g., diazepam, lorazepam, phenytoin, and phenobar-
bital).7,8 However, approximately 15% to 30% of SE episodes are
refractory to these conventional therapies. In children, the incidence
of refractory SE is not accurately known. In a study of 193 children
with SE, deﬁned by seizure duration longer than 30 min, 26% had
status epilepticus that lasted longer than 60 min.3 In the present
study, refractorySEwas identiﬁed in33%of childrenwithconvulsive
SE, a percentage that is consistent with the results, previously
published in both adult (30%) and pediatric studies (31%).18,19
The optimal management of children with refractory SE
remains unclear, and large, controlled studies comparing the
various treatment agents are lacking. The most commonly used
agent for treating refractory SE is intravenous pentobarbital, a
short-acting barbiturate with rapid onset of action. Although
effective in terminating seizures and inducing a burst suppression
pattern on EEG, pentobarbital administration is commonly
associated with signiﬁcant hypotension, myocardial depression,
and low cardiac output. Other side effects include pulmonary
edema, ileus, and delayed neurologic recovery. Because of these
disadvantages, alternative agents for the treatment of refractory SE
have been investigated. The efﬁcacy of continuous midazolam
infusion and the corresponding rate of mortality in childhood
refractory convulsive status epilepticus has been reported.20–22 In
this studywe also found that continuousmidazolam infusion up to
1.2mg/kg/min was effective in 89% of the children with refractory
SE without signiﬁcant side effects.
Midazolam is a water-soluble benzodiazepine with a fast onset
of action, that is commonly used as a preanesthetic agent with
remarkable anticonvulsant action. It also has a short half-life and
its metabolites are inactive. Midazolam has been very effective in
terminating seizures refractory to diazepam, lorazepam, phenyto-
in, and phenobarbital.8,10 It has been shown to have a wide margin
of safety and a broad therapeutic index. Furthermore, it diffuses
rapidly across the capillary wall into the central nervous system
and can be mixed with saline or glucose solutions to allow its
administration as a continuous infusion.9,21,22 A recent retrospec-
tive multicenter study found that the efﬁcacy of midazolam was
not as high as has been reported previously (64.5% versus 75–
100%).23 However, in our study we found that midazolam was
effective in 21 of 22 (95%) episodes.
Hypotension is the most commonest adverse event associated
with the administration of intravenous midazolam, but there isconsiderable variation in the prevalence of hypotension across
studies. In our study, although three patients (11%) required ﬂuid
administration to address hypotension they did not require
inotropic support. This mirrors the ﬁnding of Igartua et al.24 in a
study that is also notable for the relatively high doses of
midazolam employed. Morrison et al.25 reported that in 12% of
patients required ﬂuid administration, Singhi et al.26 recorded
hypotension in 28% (6/21) of patients started on intravenous
midazolam therapy.
Status epilepticus occurs more often in young children. More
than 80% of the younger children in our study had status
epilepticus of febrile or acute symptomatic etiology, whereas
older children were more likely to be in the cryptogenic or remote
symptomatic categories. The older children were also more likely
to be neurologically abnormal (55% versus 21%) and to have a
history of seizures (64% versus 20%) than those children younger
than two years of age.18,19 In our series, all status episodes were
seen in a relatively young population (mean age 3.8  1.8 years).
While the majority (85%) of febrile episodes occurred in younger
patients, afebrile refractory episodes were more likely to be seen in
older patients (53.3%) (p = 0.004) (95% CI). Based on these and
previously reported ﬁndings in young children, it appears that
episodes in young children occur primarily in children who are
neurologically normal and with no history of unprovoked seizures. In
older children, status epilepticus occurs primarily in those who are
known to have prior unprovoked seizures and who are often also
neurologically abnormal. Although the sex ratio (male/female) of our
patients was 1.7, which is similar to ratios in previous reports4,27 and
this male preponderance should be investigated in future studies.
Similar to most of the previous studies, the most common
underlying cause of status epilepticus in these children particu-
larly in the early and established groups were febrile seizures/CNS
infections and idiopathic seizures (66%). The other main causes of
status epilepticus in our series were cerebral-dysgenesis/congeni-
tal cerebral abnormalities, anoxia/hypoxic ischemic encephalopa-
thy and trauma. Overall, our data on etiology is concordant with
that from other studies in the literature.4,23
Neurological sequelae have been reported in more than 50% of
patients with refractory status epilepticus.24,28–33 Neurological
sequelae are associated with age of the child and the underlying
causes. However, the incidence of sequelae was primarily
dependent on duration of follow-up (at discharge; 54%, at one
month; 32%, at 1 year; 23%). In our study, this incidence was 15%
among all of our study patients (4/10, 40% of patients with
refractory status epilepticus). We believe that this low rate as
strongly associated with the inclusion of younger patients and
more febrile episodes.
In the present study, we assessed our institutional treatment
protocol for convulsive SE. Using this protocol, we found that
midazolam infusion was successful in 95% of cases. Only 7.5% of
cases responded to ﬁrst-line therapy with diazepam, which
indicates that step 1 was a failure. Only 11% responded to a
midazolam bolus used in the second step, which could also be
interpreted as a failure, whereas eight of nine children with
refractory SE responded to a midazolam infusion. Since a
midazolam infusion up to 1.2 mg is safe, and there were not
signiﬁcant side effects. We conclude that combined benzodiaze-
pine therapy (diazepam in step I and midazolam in step II and step
III) is effective and safe.
In the present institutional protocol, intravenous (iv) valproate
and iv levetiracetam were not included for the treatment of
established and refractory cases. However both drugs have been
suggested for treatment of established and refractory SE.34–37
Refractory SE can be controlled with intravenous loading and
maintenance of valproate or levetiracetam which do not cause
respiratory depression or hypotension and do not require the
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levetiracetam were released into the market in Turkey in 2008.
This recent release of these drugs precluded their use in this
protocol. These two drugs also should be tested in the institutional
treatment protocols for pediatric status epilepticus.
In conclusion, Ege Pediatric Status Epilepticus Treatment
Protocol (EPSEP) using combined benzodiazepines (diazepam + -
midazolam) as initial treatment is an effective and safe regimen for
children with convulsive status epilepticus. The protocol should be
studied in a large, prospective, randomized, multicenter trial so
that physicians can implement evidence-based treatment strate-
gies for the treatment of pediatric status epilepticus.
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